



**Mario Campone**

**Kontakt**

Mario Campone

## Publikationen (6)

Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolane S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. *Ann Oncol* 2024

Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe G, Cicin I, Tolane S, Goetz M, Rugo H, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol* 2022

Johnston S, Huober J, Wardley A, Tolane S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol* 2020; 38:3987-3998.

Goetz M, Bourayou N, Smith I, Barriga S, Frenzel M, Forrester T, Garnica Jaliffe G, Freedman O, Manso L, Chen S, Trédan O, Park I, Huober J, Paluch-Shimon S, Sohn J, Campone M, Toi M, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol* 2017; 35:3638-3646.

Wick W, Golfopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). *Clin Cancer Res* 2016; 22:4797-4806.

Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Res Treat* 2014; 144:321-9.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)